pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 29 | Non-oncology: 17 Oncology: 12 |
| Under Consideration for Negotiation | 18 | Non-oncology: 7 Oncology: 11 |
| Completed Negotiations | 885 | With Letter of Intent: 768 Without agreement: 117 |
| Negotiations That Were Not Pursued | 114 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Elahere | AbbVie Corporation | For the treatment of adult patients with folate receptor-alpha (FRα) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. | |
| Scemblix | Novartis Pharmaceuticals Canada Inc. | For the treatment of adult patients with newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) (first line). | |
| Columvi | Hoffmann-La Roche Ltd. | In combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT). | |
| Voranigo | Servier Canada Inc. | For the treatment of Grade 2 WHO 2016, 2021 grading system astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and olde |